How to buy Bolt Biotherapeutics stock | $17.51

Bolt Biotherapeutics, a San Francisco-based company that develops immuno-oncology therapeutics, completed an upsized $220 million IPO, selling 11.5 million shares $20 each.

The stock opened at $26.10 on Friday and jumped more than 25% shortly after it opened for trading.

Bolt Biotherapeutics stock price (NASDAQ: BOLT)

Use our graph to track the performance of BOLT stocks over time.

Bolt Biotherapeutics shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$17.51
52-week range	$11.20 - $43.07
50-day moving average	$14.88
200-day moving average	$23.21
Wall St. target price	$39.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Bolt Biotherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Bolt Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Bolt Biotherapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bolt Biotherapeutics price performance over time

Historical closes compared with the close of $17.51 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	14.15%
3 months (2021-05-03)	-28.91%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Bolt Biotherapeutics financials

Revenue TTM	$67,000
Gross profit TTM	$-40,126,000
Return on assets TTM	-18.73%
Return on equity TTM	-45.71%
Profit margin	0%
Book value	$8.35
Market capitalisation	$446.6 million

TTM: trailing 12 months

Shorting Bolt Biotherapeutics shares

There are currently 1.8 million Bolt Biotherapeutics shares held short by investors – that's known as Bolt Biotherapeutics's "short interest". This figure is 4.7% down from 1.9 million last month.

There are a few different ways that this level of interest in shorting Bolt Biotherapeutics shares can be evaluated.

Bolt Biotherapeutics's "short interest ratio" (SIR)

Bolt Biotherapeutics's "short interest ratio" (SIR) is the quantity of Bolt Biotherapeutics shares currently shorted divided by the average quantity of Bolt Biotherapeutics shares traded daily (recently around 199177.04918033). Bolt Biotherapeutics's SIR currently stands at 9.15. In other words for every 100,000 Bolt Biotherapeutics shares traded daily on the market, roughly 9150 shares are currently held short.

To gain some more context, you can compare Bolt Biotherapeutics's short interest ratio against those of similar companies.

• Seagen (SGEN.US): 3.58
• MacroGenics (MGNX.US): 4.47
• Merus N-V (MRUS.US): 6.52

However Bolt Biotherapeutics's short interest can also be evaluated against the total number of Bolt Biotherapeutics shares, or, against the total number of tradable Bolt Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bolt Biotherapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Bolt Biotherapeutics shares in existence, roughly 50 shares are currently held short) or 0.1091% of the tradable shares (for every 100,000 tradable Bolt Biotherapeutics shares, roughly 109 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Bolt Biotherapeutics.

Find out more about how you can short Bolt Biotherapeutics stock.

Bolt Biotherapeutics share dividends

We're not expecting Bolt Biotherapeutics to pay a dividend over the next 12 months.

Bolt Biotherapeutics overview

Bolt Biotherapeutics, Inc. , a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.

Frequently asked questions

What percentage of Bolt Biotherapeutics is owned by insiders or institutions?
Currently 3.626% of Bolt Biotherapeutics shares are held by insiders and 87.049% by institutions. How many people work for Bolt Biotherapeutics?
Latest data suggests 65 work at Bolt Biotherapeutics. When does the fiscal year end for Bolt Biotherapeutics?
Bolt Biotherapeutics's fiscal year ends in December. Where is Bolt Biotherapeutics based?
Bolt Biotherapeutics's address is: 900 Chesapeake Drive, Redwood City, CA, United States, 94063